ID.1
Item
active ra, characterised by a das28 (crp)(disease activity score based on 28 joints and crp) above 3.2 and a minimum of two swollen joints based on a 68/66 joint count at screening
boolean
ID.2
Item
concomitant treatment with mtx (7.5 - 25 mg/week both inclusive) for at least 16 weeks, with a stable dose for at least 6 weeks prior to dosing
boolean
ID.3
Item
subjects with chronic inflammatory autoimmune disease other than ra
boolean
ID.4
Item
history of or current inflammatory joint disease other than ra such as gout (crystal proven), psoriatic arthritis, juvenile idiopathic arthritis, current reactive arthritis or lyme disease
boolean
ID.5
Item
any active or ongoing chronic infectious disease (e.g. chronic osteomyelitis, chronic pyelonephritis) requiring systemic anti-infectious treatment within 4 weeks prior to randomisation
boolean
ID.6
Item
clinically significant cardiac or cardiovascular disease
boolean
ID.7
Item
past or current malignancy
boolean
ID.8
Item
latent or active tuberculosis (tb) as documented by: a positive quantiferon® test (test can be performed up to 2 months prior to dosing). one retest is allowed in case of inconclusive results.- a history of active tb within the last 3 years even, if treated effectively. - a history of active tb more than 3 years ago, if there is no documentation that the prior anti-tb treatment was appropriate in duration and type
boolean